UNSPSC 51262903: Levomoprolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C13H21NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier K4NON6FSON, chemically known as 2-propanol, 1-(2-methoxyphenoxy)-3-((1-methylethyl)amino)-, (s)- but generally known as levomoprolol, which bears US NIH Compound Identifier 3034006. European Medicines Agency schedules Levomoprolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08480MIG.

UNSPSC 51262903 Levomoprolol is a Commodity code that captures pharmaceutical products, though the recent state and local procurement activity under this code shows minimal direct alignment with the code's nominal scope. Levomoprolol is a beta-blocker pharmaceutical, but the single recent opportunity posted under this code — Seminole County, Florida's IFB60459723LAS — solicits naloxone and drug deactivation systems for community health support, a product category distinct from the code's stated focus. The mismatch suggests either misclassification by the issuing body or a data-tagging error in the procurement system. State and local governments appear to use this code sparingly, if at all, for its intended pharmaceutical purpose.

Seminole County posted the only recent opportunity under this code, issued as an IFB on June 30, 2026, with a response deadline of July 26, 2023 (an apparent date inconsistency in the source record). The county sought 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida. The procurement included standard compliance requirements — E-Verify authorization, drug-free workplace certification, and workers' compensation insurance — with an initial two-year contract term and optional one-year renewal. Bidders were required to submit electronically through the county's e-Procurement Portal and include all shipping and delivery costs in their proposals. The contract was potentially FEMA-funded, introducing additional federal compliance obligations. No explicit set-aside designations were noted. The narrow activity under this code and the mismatch between the code's pharmaceutical focus and naloxone/drug-deactivation procurement suggests this is not a high-activity category for state and local procurement.